Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 469 to 480 of 498 entries
Sorted by: Best Match Show Resources per page
Health and Brexit: what lies ahead?.

The Lancet. Haematology

The Lancet Haematology.
PMID: 30824034
Lancet Haematol. 2019 Mar;6(3):e110. doi: 10.1016/S2352-3026(19)30019-5.

No abstract available.

Cite
The Lancet Haematology. Health and Brexit: what lies ahead?. Lancet Haematol. 2019;6(3):e110doi: 10.1016/S2352-3026(19)30019-5.
The Lancet Haematology. (2019). Health and Brexit: what lies ahead?. The Lancet. Haematology, 6(3), e110. https://doi.org/10.1016/S2352-3026(19)30019-5
The Lancet Haematology. "Health and Brexit: what lies ahead?." The Lancet. Haematology vol. 6,3 (2019): e110. doi: https://doi.org/10.1016/S2352-3026(19)30019-5
The Lancet Haematology. Health and Brexit: what lies ahead?. Lancet Haematol. 2019 Mar;6(3):e110. doi: 10.1016/S2352-3026(19)30019-5. PMID: 30824034.
Copy Download .nbib Format: NLM
Brexit and the NHS.

Lancet (London, England)

The Lancet.
PMID: 29595480
Lancet. 2018 Mar 24;391(10126):1122. doi: 10.1016/S0140-6736(18)30625-1.

No abstract available.

Cite
The Lancet. Brexit and the NHS. Lancet. 2018;391(10126):1122doi: 10.1016/S0140-6736(18)30625-1.
The Lancet. (2018). Brexit and the NHS. Lancet (London, England), 391(10126), 1122. https://doi.org/10.1016/S0140-6736(18)30625-1
The Lancet. "Brexit and the NHS." Lancet (London, England) vol. 391,10126 (2018): 1122. doi: https://doi.org/10.1016/S0140-6736(18)30625-1
The Lancet. Brexit and the NHS. Lancet. 2018 Mar 24;391(10126):1122. doi: 10.1016/S0140-6736(18)30625-1. PMID: 29595480.
Copy Download .nbib Format: NLM
Uphold Hawking's and Sulston's support for European science.

Nature

Heuer R, Nurse P.
PMID: 29620736
Nature. 2018 Apr 05;556(7699):31. doi: 10.1038/d41586-018-04049-9.

No abstract available.

Cite
Heuer R, Nurse P. Uphold Hawking's and Sulston's support for European science. Nature. 2018;556(7699):31doi: 10.1038/d41586-018-04049-9.
Heuer, R., & Nurse, P. (2018). Uphold Hawking's and Sulston's support for European science. Nature, 556(7699), 31. https://doi.org/10.1038/d41586-018-04049-9
Heuer, Rolf, and Nurse, Paul. "Uphold Hawking's and Sulston's support for European science." Nature vol. 556,7699 (2018): 31. doi: https://doi.org/10.1038/d41586-018-04049-9
Heuer R, Nurse P. Uphold Hawking's and Sulston's support for European science. Nature. 2018 Apr 05;556(7699):31. doi: 10.1038/d41586-018-04049-9. PMID: 29620736.
Copy Download .nbib Format: NLM
The New Political Economy of Health Care in the European Union: The Impact of Fiscal Governance.

International journal of health services : planning, administration, evaluation

Greer SL, Jarman H, Baeten R.
PMID: 27076653
Int J Health Serv. 2016;46(2):262-82. doi: 10.1177/0020731416637205.

We argue that the political economy of health care in the European Union is being changed by the creation of a substantial new apparatus of European fiscal governance. A series of treaties and legal changes since 2008 have given...

Cite
Greer SL, Jarman H, Baeten R. The New Political Economy of Health Care in the European Union: The Impact of Fiscal Governance. Int J Health Serv. 2016;46(2):262-82doi: 10.1177/0020731416637205.
Greer, S. L., Jarman, H., & Baeten, R. (2016). The New Political Economy of Health Care in the European Union: The Impact of Fiscal Governance. International journal of health services : planning, administration, evaluation, 46(2), 262-82. https://doi.org/10.1177/0020731416637205
Greer, Scott L, et al. "The New Political Economy of Health Care in the European Union: The Impact of Fiscal Governance." International journal of health services : planning, administration, evaluation vol. 46,2 (2016): 262-82. doi: https://doi.org/10.1177/0020731416637205
Greer SL, Jarman H, Baeten R. The New Political Economy of Health Care in the European Union: The Impact of Fiscal Governance. Int J Health Serv. 2016;46(2):262-82. doi: 10.1177/0020731416637205. PMID: 27076653.
Copy Download .nbib Format: NLM
Introduction to BJS special issue.

The British journal of sociology

Dodd N, Lamont M, Savage M.
PMID: 29114867
Br J Sociol. 2017 Nov;68:S3-S10. doi: 10.1111/1468-4446.12326.

No abstract available.

Cite
Dodd N, Lamont M, Savage M. Introduction to BJS special issue. Br J Sociol. 2017;68:S3-S10doi: 10.1111/1468-4446.12326.
Dodd, N., Lamont, M., & Savage, M. (2017). Introduction to BJS special issue. The British journal of sociology, 68S3-S10. https://doi.org/10.1111/1468-4446.12326
Dodd, Nigel, et al. "Introduction to BJS special issue." The British journal of sociology vol. 68 (2017): S3-S10. doi: https://doi.org/10.1111/1468-4446.12326
Dodd N, Lamont M, Savage M. Introduction to BJS special issue. Br J Sociol. 2017 Nov;68:S3-S10. doi: 10.1111/1468-4446.12326. PMID: 29114867.
Copy Download .nbib Format: NLM
Brexit, Trump, and 'methodological whiteness': on the misrecognition of race and class.

The British journal of sociology

Bhambra GK.
PMID: 29114873
Br J Sociol. 2017 Nov;68:S214-S232. doi: 10.1111/1468-4446.12317.

The rhetoric of both the Brexit and Trump campaigns was grounded in conceptions of the past as the basis for political claims in the present. Both established the past as constituted by nations that were represented as 'white' into...

Cite
Bhambra GK. Brexit, Trump, and 'methodological whiteness': on the misrecognition of race and class. Br J Sociol. 2017;68:S214-S232doi: 10.1111/1468-4446.12317.
Bhambra, G. K. (2017). Brexit, Trump, and 'methodological whiteness': on the misrecognition of race and class. The British journal of sociology, 68S214-S232. https://doi.org/10.1111/1468-4446.12317
Bhambra, Gurminder K. "Brexit, Trump, and 'methodological whiteness': on the misrecognition of race and class." The British journal of sociology vol. 68 (2017): S214-S232. doi: https://doi.org/10.1111/1468-4446.12317
Bhambra GK. Brexit, Trump, and 'methodological whiteness': on the misrecognition of race and class. Br J Sociol. 2017 Nov;68:S214-S232. doi: 10.1111/1468-4446.12317. PMID: 29114873.
Copy Download .nbib Format: NLM
Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.

AAPS PharmSciTech

Cilia M, Ruiz S, Richardson P, Salmonson T, Serracino-Inglott A, Wirth F, Borg JJ.
PMID: 29027130
AAPS PharmSciTech. 2018 Feb;19(2):489-511. doi: 10.1208/s12249-017-0892-0. Epub 2017 Oct 12.

The aim of this study was to identify trends in deficiencies raised during the EU evaluation of the quality part of dossiers for marketing authorisation applications of biosimilar medicinal products. All adopted day 120 list of questions on the...

Cite
Cilia M, Ruiz S, Richardson P, et al. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. AAPS PharmSciTech. 2017;19(2):489-511doi: 10.1208/s12249-017-0892-0.
Cilia, M., Ruiz, S., Richardson, P., Salmonson, T., Serracino-Inglott, A., Wirth, F., & Borg, J. J. (2018). Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. AAPS PharmSciTech, 19(2), 489-511. https://doi.org/10.1208/s12249-017-0892-0
Cilia, Mark, et al. "Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use." AAPS PharmSciTech vol. 19,2 (2018): 489-511. doi: https://doi.org/10.1208/s12249-017-0892-0
Cilia M, Ruiz S, Richardson P, Salmonson T, Serracino-Inglott A, Wirth F, Borg JJ. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. AAPS PharmSciTech. 2018 Feb;19(2):489-511. doi: 10.1208/s12249-017-0892-0. Epub 2017 Oct 12. PMID: 29027130.
Copy Download .nbib Format: NLM
Brexit is bad for health, and doctors should say so.

BMJ (Clinical research ed.)

Modi N.
PMID: 28495663
BMJ. 2017 May 11;357:j2265. doi: 10.1136/bmj.j2265.

No abstract available.

Cite
Modi N. Brexit is bad for health, and doctors should say so. BMJ. 2017;357:j2265doi: 10.1136/bmj.j2265.
Modi, N. (2017). Brexit is bad for health, and doctors should say so. BMJ (Clinical research ed.), 357j2265. https://doi.org/10.1136/bmj.j2265
Modi, Neena. "Brexit is bad for health, and doctors should say so." BMJ (Clinical research ed.) vol. 357 (2017): j2265. doi: https://doi.org/10.1136/bmj.j2265
Modi N. Brexit is bad for health, and doctors should say so. BMJ. 2017 May 11;357:j2265. doi: 10.1136/bmj.j2265. PMID: 28495663.
Copy Download .nbib Format: NLM
Is there Europeanization of physical activity promotion? - A neofunctional approach.

Health policy (Amsterdam, Netherlands)

Mnich C.
PMID: 30665712
Health Policy. 2019 Mar;123(3):317-326. doi: 10.1016/j.healthpol.2019.01.004. Epub 2019 Jan 14.

Physical inactivity is a problem in Europe, contributing to various non-communicable diseases (NCDs). While health sciences offer data and models for preventing the development of NCDs through health promotion, they do not explain the dynamics between the different institutions...

Cite
Mnich C. Is there Europeanization of physical activity promotion? - A neofunctional approach. Health Policy. 2019;123(3):317-326doi: 10.1016/j.healthpol.2019.01.004.
Mnich, C. (2019). Is there Europeanization of physical activity promotion? - A neofunctional approach. Health policy (Amsterdam, Netherlands), 123(3), 317-326. https://doi.org/10.1016/j.healthpol.2019.01.004
Mnich, Carina. "Is there Europeanization of physical activity promotion? - A neofunctional approach." Health policy (Amsterdam, Netherlands) vol. 123,3 (2019): 317-326. doi: https://doi.org/10.1016/j.healthpol.2019.01.004
Mnich C. Is there Europeanization of physical activity promotion? - A neofunctional approach. Health Policy. 2019 Mar;123(3):317-326. doi: 10.1016/j.healthpol.2019.01.004. Epub 2019 Jan 14. PMID: 30665712.
Copy Download .nbib Format: NLM
Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.

Clinical and translational science

Morant AV, Jagalski V, Vestergaard HT.
PMID: 30681284
Clin Transl Sci. 2019 Jul;12(4):361-370. doi: 10.1111/cts.12617. Epub 2019 Mar 02.

For regulatory approval of a new medicine, the gold standard for demonstration of efficacy has traditionally been a minimum of two positive, adequate, and well-controlled clinical trials. Nevertheless, drugs to treat cancer and rare diseases are usually approved based...

Cite
Morant AV, Jagalski V, Vestergaard HT. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016. Clin Transl Sci. 2019;12(4):361-370doi: 10.1111/cts.12617.
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019). Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016. Clinical and translational science, 12(4), 361-370. https://doi.org/10.1111/cts.12617
Morant, Anne Vinther, et al. "Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016." Clinical and translational science vol. 12,4 (2019): 361-370. doi: https://doi.org/10.1111/cts.12617
Morant AV, Jagalski V, Vestergaard HT. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016. Clin Transl Sci. 2019 Jul;12(4):361-370. doi: 10.1111/cts.12617. Epub 2019 Mar 02. PMID: 30681284; PMCID: PMC6662549.
Copy Download .nbib Format: NLM
Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.

Clinical therapeutics

Rokuda M, Matsumaru N, Tsukamoto K.
PMID: 29361305
Clin Ther. 2018 Feb;40(2):284-295. doi: 10.1016/j.clinthera.2017.12.010. Epub 2018 Feb 01.

PURPOSE: Multiregional clinical trials (MRCT) are a standard strategy used to improve global drug approval efficiency and the feasibility of clinical trials. Japan is the world's third largest drug market with a unique health care system, making it a...

Cite
Rokuda M, Matsumaru N, Tsukamoto K. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clin Ther. 2018;40(2):284-295doi: 10.1016/j.clinthera.2017.12.010.
Rokuda, M., Matsumaru, N., & Tsukamoto, K. (2018). Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clinical therapeutics, 40(2), 284-295. https://doi.org/10.1016/j.clinthera.2017.12.010
Rokuda, Mitsuhiro, et al. "Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan." Clinical therapeutics vol. 40,2 (2018): 284-295. doi: https://doi.org/10.1016/j.clinthera.2017.12.010
Rokuda M, Matsumaru N, Tsukamoto K. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clin Ther. 2018 Feb;40(2):284-295. doi: 10.1016/j.clinthera.2017.12.010. Epub 2018 Feb 01. PMID: 29361305.
Copy Download .nbib Format: NLM
Exploring the impact of Brexit.

British journal of nursing (Mark Allen Publishing)

Foster S.
PMID: 30281344
Br J Nurs. 2018 Oct 04;27(18):1085. doi: 10.12968/bjon.2018.27.18.1085.

Sam Foster, Chief Nurse, Oxford University Hospitals, presents a risk assessment of the potential effects of leaving the European Union on nursing and the NHS more widely.

Cite
Foster S. Exploring the impact of Brexit. Br J Nurs. 2018;27(18):1085doi: 10.12968/bjon.2018.27.18.1085.
Foster, S. (2018). Exploring the impact of Brexit. British journal of nursing (Mark Allen Publishing), 27(18), 1085. https://doi.org/10.12968/bjon.2018.27.18.1085
Foster, Sam. "Exploring the impact of Brexit." British journal of nursing (Mark Allen Publishing) vol. 27,18 (2018): 1085. doi: https://doi.org/10.12968/bjon.2018.27.18.1085
Foster S. Exploring the impact of Brexit. Br J Nurs. 2018 Oct 04;27(18):1085. doi: 10.12968/bjon.2018.27.18.1085. PMID: 30281344.
Copy Download .nbib Format: NLM
Showing 469 to 480 of 498 entries